Back
Lineage Cell Therapeutics, Inc. 10K Form
Sell
36
LCTX
Lineage Cell Therapeutics, Inc.
Last Price:
$1.71
Seasonality Move:
11.05%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
10K form not available
Receive LCTX News And Ratings
See the #1 stock for the next 7 days that we like better than LCTX
LCTX Financial Statistics
Sales & Book Value
| Annual Sales: | $9.5M |
|---|---|
| Cash Flow: | $-3.6M |
| Price / Cash Flow: | 0 |
| Annual Sales: | $0.10 |
| Price / Book: | 17.97 |
Profitability
| EPS (TTM): | -0.29660 |
|---|---|
| Net Income (TTM): | $-67.5M |
| Gross Margin: | $8.6M |
| Return on Equity: | -117.46% |
| Return on Assets: | -67.24% |
Lineage Cell Therapeutics, Inc. Earnings Forecast
Key Lineage Cell Therapeutics, Inc. Financial Ratios
-
The Gross Profit Margin over the past 33 years for LCTX is 90.07%.
-
The Selling, General & Administrative Expenses for LCTX have been equal to 191.29% of Gross Profit Margin.
-
The Research & Development expenses have been 131.07% of Revenue.
-
The Net Earning history of LCTX is -195.62% of Total Revenues.
-
Per Share Earnings over the last 33 years have been positive in 15 years.
Lineage Cell Therapeutics, Inc. Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NYAM |
|---|---|
| Industry: | Biotechnology |
| Sector: | Health Care |
| Current Symbol: | LCTX |
| CUSIP: | 53566P |
| Website: | lineagecell.com |
Debt
| Debt-to-Equity Ratio: | 0.12 |
|---|---|
| Current Ratio: | 4.5 |
| Quick Ratio: | 4.39 |
Price-to-Earnings
| Trailing P/E Ratio: | 0 |
|---|---|
| Forward P/E Ratio: | 0 |
LCTX Technical Analysis vs Fundamental Analysis
Sell
36
Lineage Cell Therapeutics, Inc. (LCTX)
is a Sell
Is Lineage Cell Therapeutics, Inc. a Buy or a Sell?
-
Lineage Cell Therapeutics, Inc. stock is rated a SellThe current Lineage Cell Therapeutics, Inc. [LCTX] share price is $1.72. The Score for LCTX is 36, which is 28% below its historic median score of 50, and infers higher risk than normal.